Thank you Nasdaq for recognizing our Series B financing news on the Times Square tower in NYC!
Cardurion Pharmaceuticals
Biotechnology Research
Burlington, Massachusetts 2,642 followers
Translating the science of cardiac myocyte signaling pathways into groundbreaking therapeutics
About us
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.
- Website
-
http://www.cardurion.com
External link for Cardurion Pharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Burlington, Massachusetts
- Type
- Privately Held
- Founded
- 2017
- Specialties
- Biotechnology, Therapeutics, Cardiovascular, Heart Failure, and Cardiology
Locations
-
Primary
78 Blanchard Road
Suite 200
Burlington, Massachusetts 01803, US
-
26-1, Muraoka-Higashi 2-chome
Fujisawa, Kanagawa 251-8555, JP
Employees at Cardurion Pharmaceuticals
Updates
-
Read about our financing news in BioSpace. #heartfailure #cardiovasculardisease #CVdruginnovation https://lnkd.in/e-pvXbmy
-
BioPharma Dive digs into our financing news and our approach to creating new treatments for #cardiovasculardisease. https://lnkd.in/dcfggGar
Cardurion raises another $260M to fuel heart drug pipeline
biopharmadive.com
-
Cardurion is positioned for our next stage of growth, fueled by a strong syndicate of investors and our passionate team of experts in #cardiovasculardisease. We are ready to advance groundbreaking medicines to address unmet needs for patients. #heartfailure #cardiovasculardisease #CVdruginnovation https://lnkd.in/eS8XMqeq
-
-
We appreciate the strong support of our Series B syndicate, led by Ascenta Capital, and joined by existing investors, Bain Capital Life Sciences and Bain Capital Private Equity, and new investors, NEA, GV, Fidelity Management & Research Company, Millennium Management, Invus, Farallon Capital Management, Blue Owl Healthcare Opportunities, Delos Capital and Digitalis Ventures. #heartfailure #cardiovasculardisease #CVdruginnovation https://lnkd.in/eS8XMqeq
-
-
Cardurion Pharmaceuticals reposted this
Today we announce a $260M Series B financing, which will support continued progress with our two clinical stage drug candidates and expansion of our #cardiovasculardisease portfolio. https://cardurion.com/ #heartfailure #CVdruginnovation https://lnkd.in/ed-h3Z-s
-
-
Today we announce a $260M Series B financing, which will support continued progress with our two clinical stage drug candidates and expansion of our #cardiovasculardisease portfolio. https://cardurion.com/ #heartfailure #CVdruginnovation https://lnkd.in/ed-h3Z-s
-
-
Though #Pride month is coming to a close, Cardurion is always a proud supporter of our LGBTQ+ community, committed to showing up in celebration, solidarity, and reflection. #loveislove #humanrights #inclusion #OneCardurion
-
-
We recognize the importance of #Juneteenth, and we celebrate this annual commemoration of the end of slavery in the United States as an official holiday at Cardurion, as part of our commitment to #diversity and #inclusion. “We must keep the faith because we are one people. We are brothers and sisters. We all live in the same house: The American house.” — John Lewis #TogetherWeRise #StrengthInUnity #CelebratingResilience #equityinscience #equityinhealthcare #OneCardurion
-
-
We agree with Dr. Carolyn Lam that it's an exciting time of innovation in approaches to treating patients with #heartfailure. Thanks for the shout-out to our PDE9 data presentation in this interview at 05:14! #HFASnacks #HeartFailure2024 #ESC #innovation https://lnkd.in/emKHDEbX
#HFASnacks by ESC TV | A new drug for heart failure? Carolyn Lam shares her insights with host, Antonio Cannata. Watch their #HFASnacks 🤗 #HeartFailure2024 #HFA_ESC | By European Society of Cardiology | Thank you everyone for joining us today for the HFASnack we are here in Lisbon. A lot of excitement, a lot of news and a lot of fun also for the attendees. So we have the pleasure of having today
facebook.com